沙库巴曲缬沙坦治疗持续性房颤的临床效果以及对心脏结构的影响  

Clinical Effect of Sackubactril and Valsartan in the Treatment of Persistent Atrial Fibrillation and Its Effect on Cardiac Structure

作　　者：袁芳[1] 

机构地区：[1]山东大学附属威海市立医院保健科,山东 威海

出　　处：《临床个性化医学》2024年第3期1035-1041,共7页Journal of Clinical Personalized Medicine

摘　　要：目的:观察沙库巴曲缬沙坦治疗持续性房颤的临床效果以及对心脏结构的影响。方法:随机选择2023年1月至2023年12月至我院进行治疗的持续性房颤患者110例,使用随机数字法将患者分为观察组和对照组各55例,分别予以沙库巴曲缬沙坦 + 胺碘酮治疗和单独应用胺碘酮治疗。比较两组患者治疗后14 d电复律比例和随访1年复发率、超声检查治疗前后左心室和左心房结构变化,以及血流动力学变化。结果:观察组患者14 d电复律治疗率、6个月和1年房颤复发率分别为20.00%、10.91%和27.27%,均低于对照组的49.49%、25.45%和58.18% (χ2 = 10.292, P = 0.001;χ2 = 3.911, P = 0.048;χ2 = 10.736, P = 0.001)。两组患者治疗前左心房内径(left anterior descending, LAD)、左心房容积(left atrial volume, LAV)、左心房容积指数(left atrial volume index, LAVI)、左心房存储应变(left atrial strain during reservoir phase, LASr)、左心室射血分数(left ventricular ejection fraction, LVEF)、舒张末期内径(left ventricular end diastolic diameter, LVEDD)、收缩末期内径(left ventricular end systolic diameter, LVESD)水平均无明显差异(P > 0.05),治疗1年后,两组患者上述指标与治疗前相比均有组内差异(P P P > 0.05),治疗后两组患者心率与治疗前相比均降低(P t = 8.651;P Objective: To observe the clinical effect of sackubactril valsartan in the treatment of persistent atrial fibrillation and its effect on cardiac structure. Methods: A total of 110 patients with persistent atrial fibrillation who were treated in our hospital from January 2023 to December 2023 were randomly selected and divided into observation group and control group by random number method, 55 patients in each group were treated with sacubactril valsartan + amiodarone or amiodarone alone. The proportion of electro cardioversion at 14 days after treatment, the recurrence rate at 1 year follow-up, the structural changes of left ventricle and left atrium before and af

关 键 词：沙库巴曲缬沙坦 持续性房颤 心脏结构 胺碘酮 

分 类 号：R54[医药卫生—心血管疾病]